Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • AGIR
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
  1. Home
  2. Investors
  3. Press releases

Press releases

25.03.2021

DEINOVE presents its financial results and the advancement of its programs for 2020

Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected mid-2021 Signature of an...
10.03.2021

DEINOVE benefits from the support of the French government, within the framework of the “France Relance” plan, to accelerate the development of new antimicrobials

DEINOVE’s Boost-ID project has been selected as part of the “France Relance” plan, a recognition of its strategic positioning. Boost-ID is...
20.01.2021

Issuance of a 5th tranche of 3 millions EUR of notes convertible into new shares

DEINOVE strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe gastrointestinal...
03.12.2020

Issuance of a 4th tranche of €1.5 million of notes convertible into new shares

DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe...
01.10.2020

2020 Half-year results: Stronger financial position and research programs moving forward despite the international context

Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United States AGIR program (...
17.06.2020

Issuance of a 3rd tranche of €1.5 million of notes convertible into new shares

DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...
04.05.2020

Alexis RIDEAU appointed Deputy Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships

• Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...
30.03.2020

In a climate of economic and industrial uncertainty, the collaboration agreement between Sharon Laboratories and Deinove will not be signed

The current health, economic and financial crisis creates too much uncertainty to enter into a long-term full partnership around a complete...
20.01.2020

DEINOVE announces its financial calendar for 2020

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
26.09.2019

2019 Half-year consolidated results: Deinove’s progress coming to fruition

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • next ›
  • last »

Investors

  • Corporate governance
    • Board of Directors
    • Executive Committee
  • DEINOVE Shares
  • Financial Calendar
  • Documentation Center
    • Financial Reports
    • Investors slide deck
    • Analyst Coverage
    • Number of Shares and Voting Rights
    • Newsletter to Shareholders
    • Shareholders' Meetings
    • Declaration of transactions performed on company securities
    • Liquidity Agreement
    • Public offerings - Documentation
    • Bonds Convertible into Shares (OCA)
  • Press releases
  • Investor relations
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

         

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home